Ross Moat
Corporate Officer/Principal at KINIKSA PHARMACEUTICALS, LTD.
Net worth: 286 620 $ as of 2024-04-29
Profile
Ross Moat is currently the Chief Commercial Officer at Kiniksa Pharmaceuticals Ltd.
He previously worked as the General Manager at Synageva BioPharma Corp.
and as the VP-EMEA Marketing & Commercial Operations at Novartis Gene Therapies, Inc. Mr. Moat completed his undergraduate degree at Middlesex University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-07 | 16,276 ( 0.04% ) | 286 620 $ | 2024-04-29 |
Ross Moat active positions
| Companies | Position | Start |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Corporate Officer/Principal | 2021-01-31 |
Former positions of Ross Moat
| Companies | Position | End |
|---|---|---|
| AVEXIS INC | Sales & Marketing | 2019-05-31 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - |
Training of Ross Moat
| Middlesex University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Private companies | 2 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Stock Market
- Insiders
- Ross Moat